Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment?: A double-blind, placebo-controlled, clinical trial

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 67-70

  Mowla, Arash ^a,b   Mosavinasab, Masoud ^a   Pani, Azadeh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDIAZEPOXIDE; FLUOXETINE; PLACEBO;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL HEALTH; MENTAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; COGNITION; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; PSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS;

EID: 33846222301     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31802e0002     Document Type: Article

References (20)

1. Smith GE, Petersen RC, Parisi JE, et al. Definition, course and outcome of mild cognitive impairment. Aging Neuropsychol Cogn. 1996;3:141-147.
2. Wenk GL, Pierce DJ, Struble RG, et al. Age related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging. 1989;10:11-19.
3. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm. 1993;91:135-159.
4. Rossor M, Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull. 1986;42:70-74.
5. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse. 1991;7:151-168.
6. Abe Y, Aoyagi A, Hara T, et al. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J Pharmacol Sci. 2003;93:95-105.
7. Gould E, McEwen BS, Tanapat P, et al. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci. 1997;17:2492-2498.
8. Manev R, Uz T, Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol. 2001;l:420.
9. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
10. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5:262-269.
11. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res. 1975;12:189-198.
12. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
13. Wechsler D. The Wechsler Memory Scale. 3rd ed. San Antonio, TX: Psychological Corp (Harcourt); 1997.
14. Hughes CP, Berg L, Danzeger W, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
15. Iverson GL. Interpreting change on the WAIS-III/WMS-III in clinical samples. Arch Clin Neuropsychol. 2001;16:183-191.
16. Berger AK, Fratiglioni L, Forsell Y, et al. The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology. 1999;53:1998-2002.
17. Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbance. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13:83-88.
18. Bradley SJ, Kulik L. Fluoxetine and memory impairment. J Am Acad Child Adolesc Psychiatry. 1993;32:1078-1079.
19. Fernández-Pérez S, Pache DM, Robert DE, et al. Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur J Pharmacol. 2005;522:78-83.
20. Geldmacher SD, Waldman AJ, Doty L, et al. Fluoxetine in dementia of Alzheimer's type: prominent adverse effects and failure to improve cognition. J Clin Psychiatry. 1994;55:161.